Re: Novartis Phase III study shows Canakinumab reduces MACE events
|
6
|
Resverlogix Corp.
|
Jun 22, 2017 02:12PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
12
|
Resverlogix Corp.
|
Nov 29, 2021 05:40PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
8
|
Resverlogix Corp.
|
Nov 29, 2021 05:46PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
2
|
Resverlogix Corp.
|
Nov 29, 2021 05:48PM
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
9
|
Resverlogix Corp.
|
Nov 29, 2021 06:14PM
|
Re: New patent application - USA Inventor
|
4
|
Resverlogix Corp.
|
May 08, 2017 03:51PM
|
Re: New patent application - USA Inventor
|
3
|
Resverlogix Corp.
|
May 10, 2017 02:08PM
|
Re: New patent application (filed January 18, 2017; published May 4, 2017)
|
2
|
Resverlogix Corp.
|
May 08, 2017 12:07PM
|
Re: New MD&A posted
|
1
|
Resverlogix Corp.
|
Dec 18, 2019 04:00PM
|
Re: New Frontiers for both RVX/Zenith
|
6
|
Resverlogix Corp.
|
Apr 18, 2017 03:56PM
|
Re: Nature Article on the role of Endothelial Cells in COVID 19 - new article
|
4
|
Resverlogix Corp.
|
Jun 03, 2020 01:58PM
|
Re: Microcap bought in CVR deal - stock is up 700%
|
1
|
Resverlogix Corp.
|
Sep 20, 2016 03:20PM
|
Re: Microcap bought in CVR deal - stock is up 700%
|
1
|
Resverlogix Corp.
|
Sep 20, 2016 03:53PM
|
Re: Microcap bought in CVR deal - stock is up 700%
|
7
|
Resverlogix Corp.
|
Sep 20, 2016 04:59PM
|
Re: Lower LDL-C and Increased Type 2 Diabetes Risk - Bear
|
9
|
Resverlogix Corp.
|
Jun 06, 2020 02:14PM
|
Re: Leading From Behind
|
10
|
Resverlogix Corp.
|
Oct 13, 2020 04:41PM
|
Re: Last pull back we bounced off the 12 DMA....
|
5
|
Resverlogix Corp.
|
Oct 11, 2016 12:57PM
|
Re: Last pull back we bounced off the 12 DMA....
|
1
|
Resverlogix Corp.
|
Oct 11, 2016 01:36PM
|
Re: Is this relevant to RVX
|
5
|
Resverlogix Corp.
|
May 17, 2020 11:21AM
|
Re: Important article published yesterday (January 4), RVX208 relevant
|
4
|
Resverlogix Corp.
|
Jan 05, 2019 12:23PM
|